Lonza
Mehdi Shafa is a highly experienced Senior Scientist at Lonza, with a focus on early-stage development of autologous and allogeneic cell therapies, including projects involving CAR-T, TCR, MSCs, HSCs, iPSCs, and Exosomes. At Lonza since December 2016, Mehdi has played a key role in the development of cGMP compliant processes and has led process characterization studies for autologous CAR-T cell therapies. Prior to this, Mehdi held positions at Ottawa Hospital Research Institute and the University of Calgary, specializing in induced pluripotent stem cells and gene editing techniques. Mehdi holds a PhD in Molecular and Medical Genetics from the University of Calgary, along with advanced degrees in Human Genetics and Biology. Additionally, Mehdi has a background in molecular diagnostics and laboratory technology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Lonza
68 followers
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a range of products for applications in nutrition, hygiene, preservation, water treatment, materials protection, and other industrial markets. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics.